ETF PROAI

IDNAvsSPMD

iShares Genomics Immunology and Healthcare ETF against SPDR Portfolio S&P 400 Mid Cap ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IDNA 169SPMD 112Oct 25Oct 26GROWTH OF $100
Head to head
IDNASPMD
Expense ratio0.47%0.030%
Assets$299M$18.1B
Net flow, 1 month+$29M+$190M
Net flow, 1 year+$83M+$2.1B
Return, YTD+59.0%+11.0%
Return, 1 year+69.0%+11.6%
Avg daily volume189K1.6M
Holdings63401
ListedJun 11, 2019Nov 8, 2005
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.